Advertisement

Topics

Influence of smoking on CYP2C19 genetic variants and clopidogrel efficacy in patients with minor stroke or TIA.

08:00 EDT 11th April 2019 | BioPortfolio

Summary of "Influence of smoking on CYP2C19 genetic variants and clopidogrel efficacy in patients with minor stroke or TIA."

Studies suggest that smoking affects clopidogrel efficacy. However, whether it influences the association between CYP2C19 genetic variants and clopidogrel efficacy is not clear.

Affiliation

Journal Details

This article was published in the following journal.

Name: European journal of neurology
ISSN: 1468-1331
Pages:

Links

DeepDyve research library

PubMed Articles [39521 Associated PubMed Articles listed on BioPortfolio]

Comparison between MassARRAY and Pyrosequencing for CYP2C19 and ABCB1 Gene Variants of Clopidogrel Efficiency Genotyping.

Clopidogrel is one of the most frequently used drugs in patients to reduce cardiovascular events. Since patients with different genetic variations respond quite differently to clopidogrel therapy, the...

Clopidogrel Pharmacogenetics.

Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles whe...

Efficacy and mechanism of loading dose clopidogrel in patients with transient ischemic attack and minor stroke.

To assess outcome, safety and possible mechanism of loading dose clopidogrel in patients with transient ischemic attack (TIA) and minor stroke. We reviewed patients with confirmed TIA and minor strok...

Genetic variants as risk factors for cigarette smoking at an early age and relapse to smoking cessation treatment: A pilot study.

Tobacco smoking is a complex and multifactorial disease involving both environmental and genetic factors. In the Mexican mestizo population, single-nucleotide polymorphisms (SNPs) associated with ciga...

CYP2C19*2 polymorphism in Polish peptic ulcer patients.

CYP2C19 isoenzyme of cytochrome P450 in the liver catabolises proton pump inhibitors, one of the therapeutics utilized in Helicobacter pylori eradication therapy, and in this way could influence the e...

Clinical Trials [9004 Associated Clinical Trials listed on BioPortfolio]

Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects

To test pharmacodynamic response to clopidogrel 150mg once daily during 7 days in healthy subjects carriers of a mutated allele (*2) associated with CYP2C19 deficiency and non responders t...

A Genomic Approach for Clopidogrel in Caribbean Hispanics

Clopidogrel is a prescription medicine used to minimize blood clot formation in patients with cardiovascular disease, particularly those undergoing heart catheterization and stroke. A subs...

Genetic Polymorphism Contributing to the Variability of Clopidogrel Response in Patients With Coronary Artery Disease

Clopidogrel non-responsiveness is probably multifactorial; several genetic and non genetic factors may contribute to impaired platelet inhibition by clopidogrel. In this regard, it is mean...

Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients

Personalized therapy as prophylaxis in ischemic stroke patients is not yet an option. From patients with ischemic heart disease, we know that patients with in vitro high on treatment plate...

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

Polymorphisms of the cytochrome P450 (CYP) 2C19 enzyme has been consistently shown to modulate clopidogrel response. Accordingly, the Food and Drug Administration (FDA) has issued a warnin...

Medical and Biotech [MESH] Definitions

Naturally occurring genetic variations associated with drug response (e.g., dosage, extent and rate of metabolic processes). While these variants are not markers for GENETIC PREDISPOSITION TO DISEASE they influence PHARMACOKINETICS and pharmacodynamics and often occur on genes encoding drug metabolism enzymes and transporters (e.g., ANGIOTENSIN CONVERTING ENZYME; CYTOCHROME P-450 CYP2D6).

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2C19.

Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP2C19.

A decrease in the incidence and frequency of SMOKING. Smoking reduction differs from SMOKING CESSATION in that the smoker continues to smoke albeit at a lesser frequency without quitting.

Pipes for smoking tobacco, cannabis, and other substances, in which smoke is drawn through water. Do not confuse with SMOKING PIPES.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topic

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...


Searches Linking to this Article